Oxford Biomedica Regulatory News (OXB)

23 Feb 2006 07:01

Oxford Biomedica PLC23 February 2006 23 FEBRUARY 2006 OXFORD BIOMEDICA: NOTICE OF FY2005 PRELIMINARY RESULTS Oxford, UK - 23 February 2006: Oxford BioMedica (LSE: OXB), the leading genetherapy company, announces that it will be releasing its preliminary results forthe twelve months ended 31 December 2005 on Tuesday, 14 March 2006. Analyst meeting: An analyst briefing will be held at 10:00 am on 14 March at the offices ofBuchanan Communications, 45 Moorfields, London EC2. Web cast: Simultaneously to the analyst briefing at 10.00 am, there will be a live audioweb cast of the results presentation. To connect to the web cast facility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/ approximately 10 minutes (09:50 am) before the startof the briefing. This will also be available for replay shortly after thepresentation. For further information, please contact:Oxford BioMedica plc:Professor Alan Kingsman, Chief Executive Tel: +44(0) 1865 783 000 City/Financial Enquiries:Lisa Baderoon/ Mark Court/ Mary-Jane JohnsonBuchanan Communications Tel: +44 (0)207 466 5000 Scientific/Trade Press Enquiries:Katja Stout/ Gemma BradleyNorthbank Communications Tel: +44 (0)207 886 8150 Notes to editors: 1. Oxford BioMedica Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in thedevelopment of novel gene-based therapeutics with a focus on the areas ofoncology and neurotherapy. The Company was established in 1995 as a spin outfrom Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica has core expertise in gene delivery, as well as in-houseclinical, regulatory and manufacturing know-how. In oncology, the pipelineincludes an immunotherapy and a gene therapy in multiple Phase II trials, and apreclinical targeted antibody therapy in collaboration with Wyeth. Inneurotherapy, the Company's lead product is a gene therapy for Parkinson'sdisease, which is expected to enter clinical trials in 2006, and four furtherpreclinical candidates. The Company is underpinned by over 80 patent families,which represent one of the broadest patent estates in the field. The Company has a staff of approximately 70 split between its main facilities inOxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.Oxford BioMedica has corporate collaborations with Wyeth, Intervet,Sigma-Aldrich, Viragen, MolMed and Kiadis; and has licensed technology to anumber of companies including Merck & Co, Biogen Idec and Pfizer. Further information is available at www.oxfordbiomedica.co.uk This information is provided by RNS The company news service from the London Stock Exchange